Clinical Evaluation of Botulinum Toxin a in the Management of Temporomandibular Myofascial Pain

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness of botulinum toxin type A (BoNT-A) in patients with temporomandibular myofascial pain who have not improved after at least 3 months of conservative treatment. Eligible patients aged 18-60 years will be randomly assigned to one of two groups: * Intervention group: Intramuscular injection of 100 U BoNT-A into the bilateral masseter and temporalis muscles. * Control group: Intramuscular injection of 0.9% normal saline (placebo) using the same technique. The primary outcomes will be: * Pain intensity, measured using a 0-10 pain scale (VAS/NRS). * Maximum mouth opening (maximal interincisal distance), measured in millimetres. Assessments will be performed before treatment (baseline) and at 1 week, 1 month, and 3 months after injection. The study will also monitor adverse events associated with the injections. The aim is to determine whether BoNT-A provides greater pain relief and improved mouth opening compared with placebo in patients with temporomandibular myofascial pain. The findings may help support the use of BoNT-A as a treatment option for patients who do not respond to conventional therapy and provide valuable evidence for clinical practice in Pakista

Inclusion Criteria: * History of TMD, no relief with conservative therapy after at least three months. * Clinical diagnosis of bilateral arthrogenous disorder and myalgia. * Moreover, TMD can be confirmed by diagnosis through MRI and CT examinations * Pregnancy or lactation. * Previous mandible or significant facial trauma. * History of prior TMD treatment or cosmetic treatments of the face with BoNT/A. * Any contraindication to BoNT/A as outlined in the XEOMIN package insert. Exclusion Criteria: \-